TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04459975

Intervention type: OTHER
Intervention: Non interventional study
Description: Comorbidities, creatinine levels, urinary analysis, hemodynamic, respiratory status, co-medication will be collected from medical files for each patient.~Specific datas from patients with AKI will be collected from medical files For severe acute patients, serum and urinary analysis will performed to identify the underlying cause of kidney injury For severe AKI patients who will die, post-mortem renal biopsy will be performed, for histopathological analysis
Study: NCT00203021

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glatiramer acetate
Description: Glatiramer acetate will be administered as per the dose and schedule specified in the respective arms.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glatiramer acetate
Description: Glatiramer acetate will be administered as per the dose and schedule specified in the respective arms.
Study: NCT03353766

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Early crossbite correction with Q-H Device
Description: Crossbite treatment in deciduous dentition with Quad-Helix appliance
Study: NCT01401699

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Optical Frequency Domain Imaging (OFDI)
Description: Optical Frequency Domain (OFDI) imaging of esophagus
Study: NCT00697294

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Tri-Vi-Sol
Description: All subjects will begin vitamin D supplementation at the first outpatient visit (at 1 week of life) and will continue through the second outpatient visit (at 3 months of age). Dosage will be 400 IU/day of vitamin D in the form of Tri-Vi-Sol vitamin drops.
Study: NCT02163213

Intervention type: OTHER
Group type: OTHER
Intervention: Serum-derived bovine immunoglobulin protein isolate (SBI)
Description: Serum-Derived Bovine Immunoglobulin /Protein Isolate (SBI) 5.0 g bid on Nutritional Status and intestinal functions in Subjects with IBS-D
Study: NCT02650128

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Shockwave Coronary Rx Lithoplasty® System
Description: The Shockwave Coronary Rx Lithoplasty® System is a proprietary balloon catheter system designed to deliver localized, lithotripsy-enhanced, balloon dilatation of calcified, stenotic, de novo coronary arteries. Energizing the lithotripsy electrodes will generate pulsatile mechanical energy within the target treatment site and will disrupt calcium within the lesion and allow subsequent dilatation of a coronary artery stenosis using low balloon pressure. The system consists of a rapid exchange balloon catheter with integrated, internal lithotripsy electrodes and a Shockwave generator.
Study: NCT03447509

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Motor Task
Description: Participants will be asked to perform specific motor tasks or movements with their fingers, hands, and arms.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Motor Task
Description: Participants will be asked to perform specific motor tasks or movements with their fingers, hands, and arms.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sham iTMS
Description: Sham or fake stimulation will be given to the brain in a non invasive manner.
Study: NCT03447509

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Training
Description: The participant will be instructed to do repetitive motor movements with their arm or hand.
Study: NCT02834104

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RMI

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: myocardial biopsy
Study: NCT02773771

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: beta-hydroxy-beta-methylbutyrate
Description: HMB is a leucine metabolite that may also be a potent mediator of anabolic processes in skeletal muscle; subjects will not receive \>3g of HMB/ day.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo is cornstarch and will be mixed in with Vital HP. The solution will look identical to the intervention arm.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vital HP®
Description: Vital HP® is a form of enteral nutrition a part of the Massachusetts General enteral formulary

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Vital HP®
Description: Vital HP® is a form of enteral nutrition a part of the Massachusetts General enteral formulary
Study: NCT01057056

Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: mind-body intervention
Description: multi-disciplinary mind-body intervention including: breathing techniques, guided imagery, meditation, touch therapy
Study: NCT01012752

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: modified allergen extract
Description: subcutaneous injections

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: subcutaneous injections
Study: NCT02048410

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Lactobacillus paracasei B21060
Description: combination of probiotic (Lactobacillus paracasei B21060) and prebiotics (arabinogalactans, xyloooligosaccarides) and amine (L-glutamine)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: low satured diet

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: low satured diet
Study: NCT01454349

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRX302
Description: Single intraprostatic injection with an ascending dose per cohort of 0.75, 1.5, 3.0, and 6.0 µg/mL

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single intraprostatic injection of matching placebo
Study: NCT04408768

Intervention type: OTHER
Intervention: standard protocol for stroke patients
Description: Standard protocol for stroke patients

Intervention type: OTHER
Intervention: standard protocol for stroke patients
Description: Standard protocol for stroke patients
Study: NCT03106285

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lactobacillus reuteri DSM17938
Description: 5 drops of active oil drops. The active dose consists of 10\^8 CFU L retueri DSM17938

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 5 drops of placebo drops
Study: NCT00175409

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Blood collection
Description: For the standard care condition, infants will remain in their isolettes and will be positioned in prone and given a pacifier to suck on throughout the blood collection.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Blood collection
Description: For the feeding condition, infants will be held and then breast fed by their mother during the blood collection.
Study: NCT04400084

Intervention type: OTHER
Intervention: Placenta perfusion
Description: Placenta perfusion in double closed circuit, during 3 hours
Study: NCT00447473

Intervention type: DRUG
Group type: OTHER
Intervention: GM-CSF
Description: GM-CSF will be administered as a subcutaneous injection at a dose of 250mcg/m2/d (maximum 500 mcg) on weeks 2 and 3 each 21 day cycle (total of 14 days).

Intervention type: DRUG
Group type: OTHER
Intervention: Ketoconazole
Description: Ketoconazole will be administered daily at a dose of 400 mg po tid (either 1 hour before or 2 hours after meals), ascorbic acid 250 mg po tid (given with ketoconazole) and replacement doses of hydrocortisone (20 mg po in the morning and 10 mg po in the evening).

Intervention type: DRUG
Group type: OTHER
Intervention: Mitoxantrone
Description: Mitoxantrone will be given at dose of 12 mg/m2 every 3 weeks, up to a maximum cumulative dose of 140 mg/m2
Study: NCT02194322

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBN 4096 BS - in single rising doses

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03227068

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PEDSS - symptom management
Description: All subjects will receive education regarding their specific disease and treatment in accordance with current practices. Cancer care providers describe detailed side effects of treatment to parents during the treatment consent process. In addition, all parents will receive standard discharge education before hospital discharge, which includes a list of home medications and information regarding whom to call for emergencies. The PEDSS - symptom management will be delivered prior to the initial hospital discharge. The nurse will review the symptom management worksheet verbally with the parent, then distribute the written worksheet to the parent.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PEDSS - support for the caregiver
Description: All subjects will receive education regarding their specific disease and treatment in accordance with current practices. Cancer care providers describe detailed side effects of treatment to parents during the treatment consent process. In addition, all parents will receive standard discharge education before hospital discharge, which includes a list of home medications and information regarding whom to call for emergencies. The PEDSS - support for the caregiver will be delivered prior to the initial hospital discharge. The nurse will review the worksheet verbally with the parent, then distribute the written worksheet to the parent.
Study: NCT02406443

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitaglitpin
Description: Oral DPP-4 inhibitor, 100 mg tablet administered once daily for 28 days

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral tablet (no medicinal ingredients) administered once daily for 28 days
Study: NCT03737331

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fractal visual cueing
Description: Walking to an external visual fractal (i.e., pink noise) stimulus.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Periodic visual cueing
Description: Walking to an external visual periodic (i.e., invariant) stimulus.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Random visual cueing
Description: Walking to an external visual random (i.e., white noise) stimulus.
Study: NCT02834104

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: blood sample
Study: NCT03410589

Intervention type: OTHER
Intervention: Sinlge arm
Description: application of scales for evaluation of sleep, fatigue and quality of life - Observational study
Study: NCT00245206

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aripiprazole
Description: Participant will take aripiprazole. Dosing will be determined by each participant's psychiatrist.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olanzapine
Description: Participant will take olanzapine. Dosing will be determined by each participant's psychiatrist.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risperidone
Description: Participant will take risperidone. Dosing will be determined by each participant's psychiatrist.
Study: NCT02499497

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LY2452473
Description: LY2452473 is a selective androgen receptor modulator which is agonist on the muscle but which spares the prostate.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LY2452473
Description: LY2452473 is a selective androgen receptor modulator which is agonist on the muscle but which spares the prostate.
Study: NCT00918658

Intervention type: OTHER
Intervention: biologic sample preservation procedure
Description: All specimens will be collected using the Pathology Residual Tissue Procurement.

Intervention type: OTHER
Intervention: biologic sample preservation procedure
Description: All specimens will be collected using the Pathology Residual Tissue Procurement.

Intervention type: OTHER
Intervention: immunologic technique
Description: Information about HLA type and immunophenotype of the malignant cells is collected from the patient's medical record.

Intervention type: OTHER
Intervention: immunologic technique
Description: Information about HLA type and immunophenotype of the malignant cells is collected from the patient's medical record.

Intervention type: OTHER
Intervention: laboratory biomarker analysis
Description: Bone marrow aspirates and/or peripheral blood samples are collected and used as target cells in standard cytotoxicity assays, with notch-induced natural killer (N-NK) cells as the effector cells, to determine whether N-NK cells are capable of killing malignant cells and/or non-malignant cells. Receptor-blocking antibodies may be added to determine which NK cell receptors are responsible for malignant cell recognition and killing.

Intervention type: OTHER
Intervention: laboratory biomarker analysis
Description: Bone marrow aspirates and/or peripheral blood samples are collected and used as target cells in standard cytotoxicity assays, with notch-induced natural killer (N-NK) cells as the effector cells, to determine whether N-NK cells are capable of killing malignant cells and/or non-malignant cells. Receptor-blocking antibodies may be added to determine which NK cell receptors are responsible for malignant cell recognition and killing.
Study: NCT01988831

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propranolol hydrochloride
Description: This intervention apply to Propranolol group
Study: NCT02499497

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LY2452473
Description: LY2452473 is a selective androgen receptor modulator which is agonist on the muscle but which spares the prostate.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The participants will receive pills containing no active drug.
Study: NCT05149963

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Therapy (CBT) for Chronic Loneliness
Description: Participants will receive an average of 12 50-minute sessions of Cognitive Behavioural Therapy (CBT) aiming to reduce their feelings of loneliness
Study: NCT04101045

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Oral Glucose Tolerance Test
Description: Each participant consumes a dinner scaled to his/her energy needs which is prepared by the metabolic kitchen. Dinner will be provided beforehand if patient does this portion at home. The participant consumes the first of three doses of D2O. Two additional doses of D20 are given at on day 1 and on day 2. The total D2O given (3 ml per kg of body water) is designed to raise body deuterium levels to 0.3% and is administered as described above to maintain steady state until the end of the study. At the HRU, an IV catheter will be inserted in order to collect blood to assess DNL. Blood draws begin during the fasting state to assess basal rates of DNL and then for six hours after the consumption of a glucose/fructose beverage (75g glucose and 25g fructose ) to assess postprandial rates of DNL. Blood draws will be taken 15 minutes before ingestion of the sugar beverage, then for every half hour for 6 hours.
Study: NCT01973608

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy (SBRT)
Description: SBRT will be administered using a dose and schedule recommended based upon the data showing the best abscopal effect using multiple fractions if one site will be targeted subject received 3 fractions (1 per day) of 8 Gray (Gy) each (total: 24 Gy). If the target lesion will be located in the thorax, the maximum total dose administered will be 18 Gy (3 x 6 Gy).

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy (SBRT)
Description: SBRT will be administered using a dose and schedule recommended based upon the data showing the best abscopal effect using multiple fractions if one site will be targeted subject received 3 fractions (1 per day) of 8 Gray (Gy) each (total: 24 Gy). If the target lesion will be located in the thorax, the maximum total dose administered will be 18 Gy (3 x 6 Gy).
Study: NCT04504942

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leronlimab
Description: Drug: Leronlimab 525mg
Study: NCT02127034

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirabegron
Description: oral
Study: NCT01988831

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo pill
Description: We use placebo pills alike propranolol commercial pills to ensure blindness of the subjects during the study.
Study: NCT03294395

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ertapenem 1000 MG
Description: single dose 1000mg intramuscular injection
Study: NCT02127034

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Solifenacin
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Solifenacin
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Digoxin
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Digoxin
Description: oral
Study: NCT03294395

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fosfomycin Oral Suspension
Description: single dose 6g oral suspension
Study: NCT00408005

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leucovorin Calcium
Description: Given PO

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mercaptopurine
Description: Given PO

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mercaptopurine
Description: Given PO
Study: NCT00408005

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mercaptopurine
Description: Given PO

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mercaptopurine
Description: Given PO
Study: NCT00955565

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Navigated
Description: Subjects receive receive computer assisted placement of the sacroiliac screws. The computer assisted placement will be performed by using the BrainLab Vector Vision®Trauma Navigation Software. Two approaches will be used, the 2D navigation and 3D navigation.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional
Description: Subjects receive standard fluoroscopic placement of the sacroiliac screw.
Study: NCT03593785

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD8233
Description: Randomized subjects will receive single SC dose of AZD8233 (dose 1, dose 2, dose 3, dose 4 and dose 5) injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD8233
Description: Randomized subjects will receive single SC dose of AZD8233 (dose 1, dose 2, dose 3, dose 4 and dose 5) injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD8233
Description: Randomized subjects will receive single SC dose of AZD8233 (dose 1, dose 2, dose 3, dose 4 and dose 5) injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD8233
Description: Randomized subjects will receive single SC dose of AZD8233 (dose 1, dose 2, dose 3, dose 4 and dose 5) injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD8233
Description: Randomized subjects will receive single SC dose of AZD8233 (dose 1, dose 2, dose 3, dose 4 and dose 5) injection.
Study: NCT02736513

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9291
Description: Patients will receive AZD9291 at a dose of 80 mg once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9291
Description: Patients will receive AZD9291 at a dose of 80 mg once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9291
Description: Patients will receive AZD9291 at a dose of 80 mg once daily.
Study: NCT02212678

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine capsule
Description: N-acetylcysteine capsule
Study: NCT02753127

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Napabucasin
Description: Napabucasin 240 mg will be administered orally, twice daily, with doses separated by approximately 12 hours (480 mg total daily dose).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluorouracil

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leucovorin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irinotecan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Study: NCT02351349

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: multidisciplinary intervention
Description: multidisciplinary intervention
Study: NCT05036200

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: pulsed dye laser
Description: four pulsed dye laser sessions were administered every eight weeks in the 21 patients
Study: NCT00046930

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: filgrastim
Description: 250 μg/m2/day by either intravenous or subcutaneous injection starting day 12, provided marrow aplasia is achieved, through recovery of absolute neutrophil count (ANC) to \> 500 cells/μl, sustained for 3 consecutive days. The dose may be rounded to the nearest vial size.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: 250 μg/m2/day by either intravenous or subcutaneous injection starting day 12, provided marrow aplasia is achieved, through recovery of absolute neutrophil count (ANC) to \> 500 cells/μl, sustained for 3 consecutive days. The dose may be rounded to the nearest vial size.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: sargramostim
Description: 5 μg/kg/day by either intravenous or subcutaneous injection starting day 12, provided marrow aplasia is achieved, through recovery of absolute neutrophil count (ANC) to \> 500 cells/μl, sustained for 3 consecutive days. The dose may be rounded to the nearest vial size.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: sargramostim
Description: 5 μg/kg/day by either intravenous or subcutaneous injection starting day 12, provided marrow aplasia is achieved, through recovery of absolute neutrophil count (ANC) to \> 500 cells/μl, sustained for 3 consecutive days. The dose may be rounded to the nearest vial size.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cytarabine
Description: 100 mg/m²/day by continuous intravenous infusion for 7 days (days 1-7).
Study: NCT00408005

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mercaptopurine
Description: Given PO

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mercaptopurine
Description: Given PO

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mercaptopurine
Description: Given PO

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mercaptopurine
Description: Given PO
Study: NCT00046930

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: 100 mg/m²/day by continuous intravenous infusion for 7 days (days 1-7).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: daunorubicin hydrochloride
Description: 45 mg/m²/day by 10 - 15 minute intravenous infusion for 3 days (days 1, 2, and 3).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: daunorubicin hydrochloride
Description: 45 mg/m²/day by 10 - 15 minute intravenous infusion for 3 days (days 1, 2, and 3).